Dr. Keith D. Wilner received his Bachelor of Arts in Chemistry from the University of Kansas and his Ph.D. in pharmacology from the University of Texas Health Science Center at Houston. After a 2-year postdoctoral fellowship at the University of California at San Diego, he joined Pfizer Global Research and Development in 1986. Dr. Wilner’s past experiences at Pfizer included overseeing the early development of potential new drug entities in the areas of Inflammation, CNS, CV, Metabolism, Immunology and Infectious Diseases; developing new strategies as they relate to the bridging of pharmacokinetic data between the U.S. and Japan and streamlining internal processes for more rapid review of safety, pharmacokinetic and pharmacodynamic data. Previously, he oversaw several early clinical development programs in the oncology therapeutic area and then moved to late clinical development where he oversaw both the clinical development of the Cyclin-Dependent Kinase (CDK) program in breast cancer and the Anaplastic Lymphoma Kinase (ALK) program in lung cancer. His current position as Executive Director in Oncology Global Product Development is overseeing the late phase clinical development programs of all lung cancer products.